Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment

http://www.actis.org/actinewl.htmi

or v iracept in patients unoergoing acute treatment tor alsseminatea IV ia mntection. r or more
information, view the Protocol Database record.
SA Phase II, Randomized, Placebo Controlled Study of the Safety and Efficacy of Viracept in
Combination with Antiretroviral Therapy in HIV Positive Women with <= 1 Month of Prior
Treatment with d4T and/or 3TC. FDA 259D. Drug: Nelfinavir.
The purpose of this Agouron Pharmaceuticals sponsored study is to find the safety, efficacy, and
pharmacokinetics of Viracept administered in combination wih d4T and 3TC in HIV positive
women with CD4 count <= 400 through evaluation of virologic, immunologic, and clinical
indicators of HIV disease progression. For more information, view the Protocol Database record.
L An Open Label, Randomized, Comparative Study of Zerit (d4T) + Epivir (3TC) + Crixivan
Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive
Subjects With CD4 Cell Counts of 200 - 700 cells/mm3 and HIV RNA Baseline Copy
Number of >= 10,000 Copies/ml. FDA 260A. Drugs: Zidovudine, Stavudine, Lamivudine,
Indinavir sulfate.
The purpose of this Bristol - Myers Squibb sponsored study is to evaluate the tolerance, and
comparative virologic and immunologic effects of the two combination regimens. For more
information, view the Protocol Database record.
L An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddl) + Crixivan
Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive
Subjects with CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of
>= 10,000 copies/ml. FDA 260B. Drugs: Zidovudine, Didanosine, Stavudine, Lamivudine,
Indinavir sulfate.
The purpose of this Bristol - Myers Squibb sponsored study is to evaluate the tolerance, and
comparative virologic and immunologic effects of the two combination regimens. For more
information, view the Protocol Database record.
Q Double-Blind Randomized Comparison Phase II Trial of Megestrol Acetate and
Testosterone Enanthate in Combination Versus Megestrol Acetate Plus Testosterone
Enanthate Placebo in Human Immunodeficiency Virus (HIV)-Associated Wasting. NIAID
ACTG 313. Drugs: Megestrol acetate, Testosterone enanthate.
The purpose of this AIDS Clinical Trials Group study is to test the hypothesis that the predominant
accrual of fat rather than lean body mass that occurs during treatment of HIV-associated wasting
with megestrol acetate may be improved by treatment with megestrol acetate and testosterone
enanthate in combination. For more information, view the Protocol Database record.
Z A Randomized, Double-Blind, Placebo-Controlled, Phase I/Il Trial of Nandrolone Decanoate
in Women With HIV-Associated Weight Loss. NIAID ACTG 329. Drug: Nandrolone
Decanoate
The purpose of this AIDS Clinical Trials Group study is to evaluate the safety of nandrolone
decanoate in women with unintentional HIV-associated weight loss and to determine whether
therapy with nandrolone decanoate can increase lean body mass in women with HIV-associated

iinint~ntinnal wuinht lticc r mnrA infcnrmntin S/a ui the PrntnrnI flot~hoea. rprnrrd

4of 10

03/17/97 15:06:48